The bill directs the Department of Health and Human Services to create a program that forms partnerships with eligible domestic PPE manufacturers to ensure a reliable supply for public health emergencies. It requires a finalization of a contractual purchasing process within one year and sets criteria that manufacturers must meet to participate.
The act also prohibits procurement of PPE manufactured outside the United States with federal funds, with specific exceptions and documentation requirements, and it commissions a follow-up report on PPE requirements and frontline safety within one year of enactment.
At a Glance
What It Does
The Secretary of Health and Human Services, working with the Assistant Secretary for Preparedness and Response, the CDC Director, and in coordination with the Secretaries of Defense and Homeland Security, will establish partnerships with eligible domestic manufacturers to secure qualified PPE for emergencies. A formal purchasing process will be finalized within one year, and contracted agreements will guarantee supplies and manufacturing capacity while accommodating additional requirements to prepare for or respond to health emergencies.
Who It Affects
Eligible domestic manufacturers, federal procurement offices, and downstream users such as hospitals and health systems that rely on PPE for emergency readiness.
Why It Matters
It formalizes a domestic PPE supply chain, raises domestic production thresholds over time, and aligns procurement with safety guidelines, aiming to reduce dependence on foreign sources during health crises.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The Domestic SUPPLY Act creates a national program that partners with US-based PPE manufacturers to ensure a ready supply for health emergencies. The program is designed to secure manufacturing capacity and keep a steady flow of qualified PPE through contractual purchasing agreements that must be finalized within a year after enactment.
The partnerships are governed by criteria that push manufacturers toward greater domestic production and rigorous quality standards. Products must meet CDC and OSHA guidelines, be 510(k) cleared, and be priced against Secretary-approved fair-market benchmarks.
The act also imposes a domestic sourcing rule for PPE used to prevent infectious disease transmission: federal funds cannot be used to procure PPE manufactured outside the United States, with defined exceptions and the requirement for documentation when exceptions apply. The legislation also calls for a one-year report detailing how PPE requirements have changed since the COVID-19 era and the impact of those changes on frontline safety.
Together, these provisions aim to strengthen national preparedness by building a domestic PPE ecosystem that is transparent, scalable, and safe for frontline workers while embedding accountability through defined timelines and reporting.
The Five Things You Need to Know
The program requires eligible domestic manufacturers to reach 50% US-made by 2026, 75% by 2027, and 100% by 2028 to participate in the partnerships.
A final process for contractual purchasing agreements must be in place within one year to enable partnerships and capacity guarantees.
Qualified PPE must meet CDC and OSHA guidelines, be 510(k) cleared, and be priced using Secretary-approved fair-market benchmarks.
Federal and state/local governments cannot fund procurement of PPE manufactured outside the United States post-enactment, with specific exceptions and documentation when used.
A report to Congress within one year will assess changes in PPE requirements since COVID-19 and their impact on frontline safety (2020-2021).
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short Title
This Act may be cited as the Domestic SUPPLY Act of 2025. It establishes the formal name and anchor for the statute that follows, setting the stage for the domestic PPE manufacturing program and related procurement rules.
National Defense and Health Security Domestic Manufacturing Partnership Program
Section 2 creates the core program. It requires the Secretary of Health and Human Services, in collaboration with the ASPR and CDC, and in coordination with the Secretaries of Defense and Homeland Security, to establish partnerships with eligible domestic manufacturers to ensure qualified PPE is available for preparing for and responding to public health emergencies. It also requires a formal process for entering into contractual purchasing agreements within one year to implement these partnerships, ensuring not only supply but also the capacity to scale production as needed. The section defines eligibility criteria for manufacturers (US-based headquarters, increasing domestic production share by 2026–2028, US ownership, supply chain security, and quality attestations) and sets out the standards for what qualifies PPE (including CDC/OSHA guidelines, 510(k) clearance, and fair-market pricing). Definitions clarify what constitutes a public health emergency and who is the Secretary.
Domestic Procurement of Clothing or Equipment Used to Prevent Transmission of Infectious Disease
Section 3 prohibits federal, state, and local governments from using new federal funds to procure PPE or related clothing/equipment that is manufactured outside the United States. It mirrors existing exceptions under 41 U.S.C. 8302, applying them to this prohibition in the same way as those exceptions apply to other restrictions. The section requires documentation, including a detailed justification, whenever an exception is used, ensuring transparency around any deviations from the domestic sourcing rule.
Report on the Impact of Changes to PPE Requirements on Frontline Worker Safety
Section 4 mandates a report to Congress within one year of enactment. The Secretary of Health and Human Services must, in consultation with the Assistant Secretary of Labor for OSHA, examine changes to federal PPE requirements since the COVID-19 pandemic and assess how those changes affected the safety of frontline physicians and other medical professionals who care for patients in person during 2020 and 2021.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Eligible domestic manufacturers that scale production and enter binding partnerships, gaining access to federal procurement and potentially steadier revenue streams.
- Federal procurement offices gain a clear framework, process, and benchmarks to procure PPE domestically.
- Hospitals, clinics, and frontline healthcare workers benefit from more predictable PPE supplies.
- Public health agencies and emergency response units secure reliable PPE supply chains for surge capacity.
Who Bears the Cost
- Manufacturers must invest to meet increasing domestic production thresholds (50% by 2026, 75% by 2027, 100% by 2028) and maintain supply chain security and quality assurances.
- Federal and state procurement agencies will implement and oversee new contracting processes and price benchmarks, which may require staffing and compliance costs.
- Smaller manufacturers that cannot meet the thresholds may face exclusion from certain federal PPE opportunities, potentially impacting market access.
- The government may incur higher upfront costs if domestic production requires capex to meet quality and capacity standards, with ongoing benchmarking and compliance oversight.
Key Issues
The Core Tension
Balancing the goal of a robust domestic PPE supply with the practical realities of manufacturing capacity and emergency procurement needs: how to require domestic production and quality without compromising timely PPE availability during public health emergencies.
The bill couples a push for domestic PPE manufacturing with new procurement controls, which creates tensions around cost, capacity, and speed in emergencies. Building a robust domestic PPE ecosystem will require substantial capital investment from manufacturers to reach the staged thresholds and to maintain secure supply chains.
There is a risk that the emphasis on 50/75/100 percent domestic production could constrain the pool of eligible suppliers or slow procurement in a rapid emergency if domestic capacity cannot meet demand. The 510(k) clearance requirement and CDC/OSHA quality benchmarks will also influence which products can be listed as qualified PPE, potentially limiting faster access if regulatory timelines lag.
The procurement ban with its exceptions raises questions about how flexible the system will be during crises, and how documentation will be handled to justify exceptions without undermining the policy’s domestic focus.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.